Autolus Therapeutics (NASDAQ:AUTL) Stock Price Up 3.7%

Autolus Therapeutics plc (NASDAQ:AUTL)’s stock price shot up 3.7% on Thursday . The company traded as high as $5.25 and last traded at $5.02. 215,735 shares traded hands during mid-day trading, a decline of 86% from the average session volume of 1,496,267 shares. The stock had previously closed at $4.84.

Analysts Set New Price Targets

A number of brokerages have recently commented on AUTL. Truist Financial increased their price objective on Autolus Therapeutics from $10.00 to $11.00 and gave the company a “buy” rating in a report on Tuesday, April 9th. Needham & Company LLC reissued a “buy” rating and issued a $9.00 price target on shares of Autolus Therapeutics in a research report on Friday, April 12th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $8.16.

Autolus Therapeutics Trading Down 5.8 %

The stock has a fifty day simple moving average of $5.89 and a 200-day simple moving average of $5.09. The stock has a market cap of $1.20 billion, a price-to-earnings ratio of -3.80 and a beta of 1.90.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Thursday, March 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.18). Sell-side analysts forecast that Autolus Therapeutics plc will post -0.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of AUTL. Cetera Investment Advisers boosted its position in shares of Autolus Therapeutics by 8.3% during the 1st quarter. Cetera Investment Advisers now owns 124,300 shares of the company’s stock valued at $518,000 after acquiring an additional 9,550 shares in the last quarter. Nantahala Capital Management LLC grew its stake in shares of Autolus Therapeutics by 6.6% in the 1st quarter. Nantahala Capital Management LLC now owns 4,346,327 shares of the company’s stock valued at $18,124,000 after purchasing an additional 268,818 shares during the period. UBS Group AG raised its holdings in shares of Autolus Therapeutics by 716.1% in the 1st quarter. UBS Group AG now owns 73,858 shares of the company’s stock worth $308,000 after buying an additional 64,808 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Autolus Therapeutics by 144.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 375,514 shares of the company’s stock worth $1,566,000 after buying an additional 222,093 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in Autolus Therapeutics in the 2nd quarter valued at $36,000. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.